BR112019008280A2 - solução farmacêutica de hidrocortisona, método para preparar a solução farmacêutica e kit de injeção - Google Patents

solução farmacêutica de hidrocortisona, método para preparar a solução farmacêutica e kit de injeção

Info

Publication number
BR112019008280A2
BR112019008280A2 BR112019008280A BR112019008280A BR112019008280A2 BR 112019008280 A2 BR112019008280 A2 BR 112019008280A2 BR 112019008280 A BR112019008280 A BR 112019008280A BR 112019008280 A BR112019008280 A BR 112019008280A BR 112019008280 A2 BR112019008280 A2 BR 112019008280A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical solution
hydrocortisone
preparing
injection kit
injection
Prior art date
Application number
BR112019008280A
Other languages
English (en)
Inventor
Flores-Ivanez Frédérique
Bardonnaud Pauline
Original Assignee
Crossject
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crossject filed Critical Crossject
Publication of BR112019008280A2 publication Critical patent/BR112019008280A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

uma solução farmacêutica de hidrocortisona compreendendo pelo menos: - hidrocortisona ou um sal farmaceuticamente aceitável da mesma; - rongalita; - edta dissódico; e - um solvente. a invenção também se refere ao seu uso no tratamento de insuficiência adrenal aguda e de asma. a invenção também se refere a um kit de injeção compreendendo um dispositivo de injeção e esta solução farmacêutica.
BR112019008280A 2016-10-26 2017-10-25 solução farmacêutica de hidrocortisona, método para preparar a solução farmacêutica e kit de injeção BR112019008280A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1660393A FR3057775B1 (fr) 2016-10-26 2016-10-26 Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
PCT/FR2017/052941 WO2018078285A1 (fr) 2016-10-26 2017-10-25 Solution pharmaceutique d'hydrocortisone pour dispositif d'injection

Publications (1)

Publication Number Publication Date
BR112019008280A2 true BR112019008280A2 (pt) 2019-07-09

Family

ID=57906786

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008280A BR112019008280A2 (pt) 2016-10-26 2017-10-25 solução farmacêutica de hidrocortisona, método para preparar a solução farmacêutica e kit de injeção

Country Status (10)

Country Link
US (1) US10456355B1 (pt)
EP (1) EP3532033B1 (pt)
JP (1) JP6665350B2 (pt)
CN (1) CN109862881A (pt)
AR (1) AR110471A1 (pt)
BR (1) BR112019008280A2 (pt)
ES (1) ES2827551T3 (pt)
FR (1) FR3057775B1 (pt)
MX (1) MX2019004173A (pt)
WO (1) WO2018078285A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3102057B1 (fr) * 2019-10-18 2021-10-29 Aguettant Lab Nouveau lyophilisat d’hémisuccinate d'hydrocortisone
CN116367835A (zh) * 2020-09-21 2023-06-30 安塔雷斯药品公司 氢化可的松磷酸钠和单硫代甘油的水性药物调配物
FR3128874A1 (fr) * 2021-11-09 2023-05-12 Crossject Solution pharmaceutique d’hydrocortisone pour dispositif d’injection
US11904046B1 (en) 2022-11-14 2024-02-20 Eton Pharmaceuticals, Inc. Hydrocortisone oral liquid formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4191106B2 (ja) * 1994-09-07 2008-12-03 ジョンソン・エンド・ジョンソン株式会社 レチノイド組成物
FR2807946B1 (fr) * 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
CN102772360B (zh) * 2012-08-22 2014-04-16 中国兽医药品监察所 一种兽用盐酸多西环素注射液及其制备方法
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015092758A1 (en) * 2013-12-19 2015-06-25 Dr. Reddy' S Laboratories Ltd Liquid pharmaceutical formulations of pemetrexed
CN103816166B (zh) * 2014-02-21 2015-07-15 中国兽医药品监察所 一种兽用复方盐酸多西环素注射液及其制备方法

Also Published As

Publication number Publication date
ES2827551T3 (es) 2021-05-21
MX2019004173A (es) 2019-08-26
JP6665350B2 (ja) 2020-03-13
JP2019535668A (ja) 2019-12-12
EP3532033A1 (fr) 2019-09-04
WO2018078285A1 (fr) 2018-05-03
CN109862881A (zh) 2019-06-07
US20190314273A1 (en) 2019-10-17
AR110471A1 (es) 2019-04-03
EP3532033B1 (fr) 2020-08-05
FR3057775A1 (fr) 2018-04-27
US10456355B1 (en) 2019-10-29
FR3057775B1 (fr) 2018-11-02

Similar Documents

Publication Publication Date Title
BR112019008280A2 (pt) solução farmacêutica de hidrocortisona, método para preparar a solução farmacêutica e kit de injeção
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
BR112018077457A2 (pt) composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado
UY39706A (es) Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue
BR112017008301A2 (pt) extratos de cannabis e métodos de sua preparação e uso
ES2631504R1 (es) Medicamentos de administración nasal y métodos para su uso
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
BR112017001725A2 (pt) tratamento de esclerose lateral amiotrófica
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
BR112017016311A2 (pt) derivados de 9h-pirrolo-dipiridina
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
BR112016012615A8 (pt) sistemas, e kit
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
BR112018011319A2 (pt) novos anticorpos anti-claudina e métodos de uso
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
EA201990684A1 (ru) Способы применения оксигенированных холестеролсульфатов (ocs)
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
BR112017012337A2 (pt) Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2745 DE 15-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.